Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2019
Melbourne's Peter MacCallum Cancer Centre to be home of 'the next great wave in treatment'
25 March 2019 - A new form of cancer treatment that uses cell therapy to attack the disease will become ...
Posted by Michael Wonder on 23 Mar 2019
NICE nod for Takeda’s Adcetris in advanced stage CTCL
22 March 2019 - Takeda has announced the NICE recommendation of its advanced cutaneous T-cell lymphoma drug Adcetris (brentuximab vedotin). ...
Posted by Michael Wonder on 23 Mar 2019
Genmab announces European regulatory submission for daratumumab in combination with lenalidomide and dexamethasone in frontline multiple myeloma
22 March 2019 - Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as ...
Posted by Michael Wonder on 23 Mar 2019
A patient’s journey with melanoma and drug coverage concerns
22 March 2019 - Living her best life with her husband Jeremy, Karen Formosa was looking forward to retiring within ...
Posted by Michael Wonder on 22 Mar 2019
PBAC report - Options for listing PD-(L)1 checkpoint inhibitors for multiple cancer indications on the PBS
22 March 2019 - The PBAC Report to the Minister for Health on “Options for listing PD(L)-1 checkpoint inhibitors for multiple ...
Posted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda). ...
Posted by Michael Wonder on 20 Mar 2019
York man Paul Thomas-Peter says he could die because NHS won't fund drug
19 March 2019 - A York cancer patient says he could die because the NHS refuses to fund immunotherapy treatment ...
Posted by Michael Wonder on 20 Mar 2019
Cancer Society slams PHARMAC's treatment of patients
20 March 2019 - The Cancer Society says New Zealand patients are worse off than those in Australia. ...
Posted by Michael Wonder on 19 Mar 2019
FDA approves Genentech’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
18 March 2019 - First new initial treatment option approved by the U.S. FDA for people with ES-SCLC in more than ...
Posted by Michael Wonder on 19 Mar 2019
New treatment option now available in Canada for newly diagnosed patients with advanced lung cancer
18 March 2019 - Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy reduced the risk of death by half compared ...
Posted by Michael Wonder on 18 Mar 2019
Three new drugs added to PBS to ease cost pain
19 March 2019 - Three new treatments to help save or prolong the lives of thousands of Australians suffering from ...
Posted by Michael Wonder on 18 Mar 2019
New early breast cancer drug to reduce risk of recurrence or death approved for Australian women
18 March 2019 - Nerlynx (neratinib) now approved by the Therapeutic Goods Administration for Australian women. ...
Posted by Michael Wonder on 16 Mar 2019
Women with advanced breast cancer ask the PM to intervene
15 March 2019 - On Wednesday 13 March, ten women with advanced breast cancer presented to the Health Select Committee to ...
Posted by Michael Wonder on 15 Mar 2019
Karyopharm announces FDA extension of review period for selinexor new drug application
14 March 2019 - PDUFA action date extended by three months to July 6, 2019. ...
Posted by Michael Wonder on 14 Mar 2019
One in four cancer patients wait two months for treatment, as NHS performance hits record low
14 March 2019 - The number of cancer sufferers waiting at least two months for treatment after an urgent referral ...